Press Releases and Announcements

Interview with Rob Panting, General Manager Rentschler ATMP in Scrip: “Closing The Gaps In Gene Therapy Production”

After seven years of accelerated growth at Rentschler Biopharma SE under his leadership as CEO, Dr. Frank Mathias to return to the Supervisory Board

Rentschler Biopharma appoints Christiane Bardroff as Chief Operating Officer and Member of the Executive Board

Rentschler Biopharma appoints Tobias Glueck as Senior Vice President Human Relations

Dr. Frank Mathias in an interview with the German edition "Biotechnology 2022" of GoingPublic

Interview with Alexander Dettmer, CFO: “We equate ‘down-to-earth’ with solidity.”

European Biotechnology: Knowledge-based contract services

Ready to take off: Opportunities for developers and manufacturers in cell and gene therapy

Rentschler Biopharma appoints Mark Caswell as Vice President, Site Head for US Facility

Rentschler Biopharma contributes to Pharma´s Almanac Roundtable

Rentschler Biopharma Expands Leadership Team with Senior-Level Hires

Rentschler Biopharma adds highly experienced executive to team and provides update on progress at Rentschler ATMP

From good to great: Innovative biopharmaceutical manufacturing is key

Digital transformation: The human factor, interview with Wolfram Schulze

Rentschler Biopharma and Vetter Unveil Xpert Alliance, a Joint Visualization of their Successful Strategic Collaboration

Rentschler Biopharma further strengthens Company Leadership Team

How Science Helps Manufacturing Evolve To Meet The Complex Challenges Of Drug Development

Rentschler Biopharma reports strong growth and continues hiring at all three sites

Pharmind article on comparison of Raman and MIR spectroscopy for bioprocess monitoring of mammalian cell cultures

Rentschler Biopharma in an interview with the magazine Pharma's Almanac

Rentschler Biopharma appoints Dr. Robert Panting as General Manager of Rentschler ATMP Ltd., Center of Excellence for Cell and Gene Therapy

Rentschler Biopharma and XL-protein demonstrate efficient production of a hyperactive PASylated DNase I with extended half-life

Rentschler Biopharma Inc. recognized by Massachusetts House of Representatives as ‘Manufacturer of the Year’ for District

Rentschler Biopharma donates 50,000 Euros to support construction of the Albert Einstein Discovery Center in Ulm

Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus

Rentschler Biopharma breaks ground at new U.S. production site in greater Boston

Developing the Best Formulation Partnership

How a CDMO alliance sets new standards for drug development and commercialization

Rentschler Biopharma expands production of highly complex antibodies at German site

Vetter and Rentschler Biopharma Further Strengthen their Strategic Alliance

Rentschler Biopharma to build new cell and gene therapy capabilities in the UK

Rentschler Biopharma and Leukocare extend service offering with joint U.S. site

Our Experts featured in the European Biotechnology Spring Edition

Rentschler Biopharma establishes Center of Excellence for cell and gene therapy in the UK